Nucleos(t)ide Analog Withdrawal in Patients With Chronic HBV
Investigators assessed virological, biochemical, and clinical outcomes following cessation of nucleos(t)ide analog therapy in patients with chronic hepatitis B.
Viral Hepatitis
VIRAL HEPATITIS
Latest Articles
The Role of Fc Gamma RIIb Expression in Chronic Hepatitis B Virus Infection
Researchers conducted a study to determine the association between Fc gamma RIIb expression concentrations and chronic hepatitis B virus infection progression.
Regular Thyroid Screening Recommended for People With Hepatitis C
People with hepatitis C are at an increased risk for several autoimmune disorders. Researchers sought to discover a link between the virus and hypothyroidism.
HCV Treatment Declined Nearly Twofold Between 2015 and 2020
The COVID-19 pandemic and opioid crisis created new barriers to HCV treatment, leading to the lowest annual treatment rate in 5 years.
High Immunogenicity Observed Following 3 Doses of the 3-Antigen HBV Vaccine
Investigators assessed the manufacturing consistency, safety, and efficacy of a 3-antigen hepatitis B vaccine vs a single-antigen formulation.
Zepatier Approval Expanded to Include HCV Treatment of Pediatric Patients
The approval was based on data from a phase 2b study which evaluated Zepatier in 22 patients aged 12 to less than 18 years.
PreHevbrio, a 3-Antigen Hepatitis B Vaccine, Gets FDA Approval
PreHevbrio contains the small (S), middle (pre-S2) and large (pre-S1) hepatitis B surface antigens.
Bulevirtide BLA Submitted for Chronic Hepatitis Delta Virus Infection
The application submission is supported by data from the ongoing phase 3 MYR301 study, along with completed and ongoing phase 2 studies.
Hepatitis B Shots Advised for All US Adults Younger Than 60 Years
All U.S. adults younger than 60 years should be vaccinated against hepatitis B, the Advisory Committee on Immunization Practices recommended.
Effect of Sofosbuvir-Based Antivirals on LDL in Patients With HCV
Researchers conducted a study to determine the effect of treatment with sofosbuvir-based direct-acting antivirals on changes in low-density lipoprotein concentrations among patients with hepatitis C virus infection.
Efficacy of Long-Acting Cabotegravir Plus Rilpivirine in Patients With HIV Coinfected With Asymptomatic HCV
Researchers sought to determine the safety and efficacy of treatment with long-acting cabotegravir plus rilpivirine in patients with HIV coinfected with asymptomatic hepatitis c virus.
Projected Long-Term Impact of the COVID-19 Pandemic on Outcomes Associated With HCV
Researchers conducted a modeling study to determine the projected long-term impact of the COVID-19 pandemic on outcomes associated with hepatitis C virus care.
Medication Treatments Lacking For Active OUD in Veterans With Cirrhosis
Investigators assessed the factors associated with medication treatment for opioid use disorder and whether it is linked to hepatic decompensation or death in patients with cirrhosis and active opioid use disorder.
Outcomes of Rapid Sofosbuvir-Velpatasvir Treatment in Patients With HCV who use Injectable Drugs
Researchers conducted a study that compared rapid treatment with a 7-day course of sofosbuvir-velpatasvir with usual compare in patients with hepatitis C virus infection who use injectable drugs.
Model Evaluates HCV Elimination Forecast Among People Who Inject Drugs
Based on a mathematical model, investigators evaluated improvements to the care cascade for people with hepatitis C virus who inject drugs.
Sleep-Wake Disturbance Highly Prevalent in Populations With Liver Disease
Researchers summarized the reciprocal interaction between sleep and liver diseases, including cirrhosis, and investigated potential approaches for therapeutic interventions.
Impact of Subscription-Based Payment Models on HCV Prescription Fills Covered by Medicaid
Researchers conducted a cross-sectional study to assess the impact of subscription-based payment models on the rate of prescription fills for hepatitis C virus medications among individuals in Louisiana and Washington enrolled in Medicaid.
Hepatitis D: Recent Advances in Virology, Immunology and Treatment
Forty years after the emergence of HDV, the first anti-HDV therapeutic has been approved by the EMA, indicating the dawn of a new era for this difficult to treat disease
Effects of Short vs Standard Course Sofosbuvir-Velpatasvir in Patients With HCV
In this phase 4 non-inferiority trial, researchers compared the effects of short course vs standard course therapy with sofosbuvir-velpatasvir for the treatment of patients with hepatitis C virus.
Phase 1 Trial Data Support Safety, Efficacy of Novel HBV Treatment
Investigators assessed the safety profile and antiviral activity of the agent RO7049389 for the treatment of chronic hepatitis B virus infection.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Viral hepatitis
Loading... 
Loading...